Drugs / allo-APZ2-ACLF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03860155 | Mar 2019 → Mar 2021 | liver disorder | RHEACELL GmbH & Co. KG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-ACLF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03860155 ↗ |
| Route | Intravenous | “into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min” NCT03860155 ↗ |